Related Experiment Video
Updated: Jul 11, 2026
05:38
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Cabergoline versus levodopa monotherapy: a decision analysis
Antje M Smala1, E Annika Spottke, Olaf Machat
1Medical Economics Research Group (MERG), Munich, Germany.
Summary
Cabergoline monotherapy shows improved cost-effectiveness for early Parkinson's disease (PD) patients over 60, reducing motor complications. While initial costs are higher, it offers a favorable cost-effectiveness ratio compared to standard therapies.
Area of Science:
- Health Economics
- Neurology
- Clinical Research
Background:
- Parkinson's disease (PD) management involves balancing treatment efficacy with healthcare costs.
- Levodopa monotherapy is a common initial treatment, but motor complications can arise.
- Evaluating new therapeutic options like cabergoline is crucial for optimizing patient outcomes and resource allocation.
Purpose of the Study:
- To assess the incremental cost-effectiveness of cabergoline versus levodopa monotherapy in early Parkinson's disease (PD) within the German healthcare system.
- To analyze costs, disease progression, complication incidence, and mortality over a 10-year horizon.
- To determine the cost-effectiveness of cabergoline, particularly for different age groups.
Main Methods:
- A cost-effectiveness analysis using a Markov model with a 10-year time horizon.
- Input data derived from the "Early Treatment of PD with Cabergoline" clinical trial and German PD network cost data.
- Inclusion of direct/indirect medical and nonmedical costs, with a 5% annual discount rate and societal perspective.
Main Results:
- Cabergoline monotherapy significantly reduced motor complications compared to levodopa.
- For patients aged 60 and over, cabergoline was cost-effective per decreased Unified Parkinson's Disease Rating Scale (UPDRS) score (EUR 1,031 per point).
- Incremental cost per additional motor complication-free patient was EUR 104,400 (<60 years) and EUR 57,900 (≥60 years).
Conclusions:
- The decision-analytic model for PD, based on clinical and observed data, suggests cabergoline is a viable option.
- Despite higher initial costs, cabergoline demonstrates a cost-effectiveness ratio comparable to many established therapies.
- Cabergoline monotherapy offers a favorable economic and clinical profile for managing early Parkinson's disease, especially in older patients.
Related Concept Videos
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...